You are here

Home » Content

Nonalkolik Yağlı Karaciğer: Karaciğerin En Sık Görülen Hastalığı

NONALCOHOLIC FATTY LIVER DISEASE: THE MOST COMMONLY OCCURING LIVER DISEASE

Journal Name:

  • Türkiye Aile Hekimliği Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
Nonalcoholic Fatty Liver Disease (NAFLD) has recently gained increasing importance as the most common of all liver disor¬ders. In Western countries it is recognized in up to 70 % of autopsy series. NAFLD comprises a spectrum of chronic liver diseases, starting from a simple fatty liver which may progress to steatohepatitis, fibrosis and ultimately expand to liver cirrhosis. The link between obesity, insulin resistance and NAFLD and its more severe form called Non Alcoholic Steatohepatitis (NASH) remain as the major focus of investigation to enlight¬en the pathogenesis and the treatment of the disease. Until other evidence based pharmacological therapies gain wide acceptance, diet and exercise remain the mainstay of thera¬peutic approach to NASH. We reviewed NAFLD in this paper as it is a frequently encountered condition by the family physi¬cians.
Bookmark/Search this post with
Abstract (Original Language): 
Nonalkolik Yağlı Karaciğer Hastalığı (NAYKH), son yıllarda, en sık görülen karaciğer hastalığı olması nedeniyle büyük önem kazanmıştır. Batı ülkelerinde, otopsi serilerindeki görülme sıklığı % 70 'e varmaktadır. NAYKH başlığı altında basit bir karaciğer yağlanmasından, steatohepatit, fibroz ve sonunda karaciğer sirozuna kadar ilerleyebilen geniş bir hastalık grubu incelenmektedir. Son yıllarda, NAYKH ve onun daha ciddi formu olan Non Alkolik Steatohepatit'in (NASH) obezite, insülin rezistansı ve dislipidemilerle olan yakın ilişkisi, hastalığın mekanizması ve tedavisini aydınlatmaya yönelik en önemli araştırma odağı olmuştur. Bugün için ideal tedavisi olmayan NASH'te en sık kullanılan tavsiye kilo verme ve egzersizle sınırlı kalmakta, ilaçların olumlu etkilerine ait veriler yeterli kanıta dayanma¬makta ve farmakolojik tedavilere yönelik çalışmalar devam etmektedir. Bu yazımızda, aile hekimlerinin sıkça karşılaşabilecekleri bir hastalık olan NAYKH özetlenmiştir.
FULL TEXT (PDF): 
PDF icon arastrmx_116859_8_pp_9-13.pdf
  • 1
9-13
  • Turkish

REFERENCES

References: 

1. Diehl AM. Nonalcoholic Steatohepatitis. Semin Liv Dis 1999; 19: 221-9.
2. Daniel
S
, Ben-Menachem T, Vasudevan G, Ma CK, Blumenkehl M.
Prospective evaluation of unexplained chronic liver transaminase abnor-malties in asymptomatic and symptomatic patients. Am J Gastroenterol 1999; 94: 3010-4.
3. Bacon BR, Farahvash MJ, Janney CG, Neuschwander-Tetri BA. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994; 107: 1103-9.
4. Ludwig J, Viggiano RT, McGill DB. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980; 55: 342-8.
5. Sheth SG, Gordon FD, Chopra S. Nonalcoholic steatohepatitis. Ann Intern Med 1997; 126: 137-45.
6. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors. Hematology 1990; 12:
1106-10.
7. Younossi ZM, Matteoni CA, Gramlich T ve ark. Patient characteristics predicting cirrhosis and death in non-alcoholic steatohepatitis. Hematology 1998; 28: 303A.
8. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough A. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-19.
9. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hematology 1999; 29: 664-9.
10. Bugianesi E, Leone N, Vanni E ve ark. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002; 123: 134-40.
11. Valenti L, Fracanzani AL, Dongiovanni P ve ark. Tumor necrosis factor a promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
|
Duman DG, Tözün N | Nonalkolik Yağlı Karaciğer: Karaciğerin En Sık Görülen Hastalığı
12. Day CP, James OFW. Steatohepatitis: A tale of two "hits"? Gastroente-
rology 1998; 114: 842-5.
13. Marchesini G, Brizi M, Bianchi G. Non-alcoholic fatty liver disease. A feature of the metabolic syndrome. Diabetes 2001; 50: 1844-50.
14. Maher JJ. Cytokines: Overview. Semin Liv Dis 1999; 19(2): 109-15.
15. Wigg AJ, Roberts-Thomson IC, Dymock RB, McCarthy PJ, Grose RH, Cummins AG. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumor necrosis factor a in the pathogenesis of non-alcoholic steatohepatitis. Gut 2001; 48: 206-11.
16. Valenti L, Fracanzani AL, Dongiovanni P ve ark. Tumor necrosis factor a promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 274-80.
17. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
18. Mendler MH, Bouillet P, Le Sidaner A ve ark. Dual-energy CT in the diagnosis and quantification of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. J Hepatol 1998; 28: 785-94.
19. Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. Am J Roentgenol 1998; 171: 659-64.
20. Sanyal A. AGA technical review on nonalcoholic fatty liver disease.
Gastroenterology 2002; 123: 1705-25.
21. Teli MR, James OFW, Burt AD, Bennett MK, Day CP. The natural
history of nonalcoholic fatty liver: A follow up study. Hepatology 1995;
22: 1714-9.
22. Day CP, James OFW. Hepatic steatosis: Innocent bystander or guilty
party? Hepatology 1998; 27: 1463-6.
23. Klein S, Wadden T, Sugerman HJ. AGA technical review on obesity.
Gastroenterology2002; 123: 882-932.
24. Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steato-hepatitis: What we know in the new millennium. Am J Gastroenterol
2002; 97: 2714-24.
25. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH,
Sheppard BL. A pilot study of thiazolidinedione, troglitazone, in nonal¬coholic hepatitis. Am J Gastroenterol 2001; 96: 519-25.
26. Marchesini G, Brizi M, Giampaola B. Metformin in non-alcoholic
hepatitis. Lancet 2001; 358: 893-4.
27. Laurin J, Lindor KD, Crippin JS ve ark. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol-induced steatohepatitis: A pilot
study. Hepatology 1996; 23: 1464-7.
28. Başaranoğlu M, Acbay Ö, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis. Am J Gast-
roenterol 1999; 31: 384.
29. D'Sauza-Gburek SM, Batts KP, Nikias GA, Wiesner RH, Krom RAF. Liver transplantation for jejunoileal bypass-associated cirrhosis. Liver Transplant Surg 1997; 3: 23-7.
30. James O, Day C. Non-alcoholic steatohepatitis: another disease of aff¬luence. Lancet1999; 353: 1634-6.
31. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med 2000; 343: 1467-76.

Thank you for copying data from http://www.arastirmax.com